XPO1 mutations in cHL. (A) Schematic representation of the XPO1 protein and its functional domains, with the mutations found in cHL cases shown above. (B) Percentage of nonapoptotic cells (AnnexinV-negative by flow cytometry) assessed in 6 cHL cell lines at the indicated times after exposure to a low dose (100 nM) of the XPO1 inhibitor selinexor, or drug vehicle (dimethyl sulfoxide) as negative control (set at 100%). Day 0 corresponds to 48 hours of culture with selinexor or vehicle. Error bars refer to 3 independent experiments, each performed in triplicate; P values were calculated by 2-way ANOVA.